Mayne Pharma Group Overview
- Year Founded
-
1845

- Status
-
Public
- Employees
-
160

- Stock Symbol
-
MYX

- Investments
-
17
- Share Price
-
$3.64
- (As of Monday Closing)
Mayne Pharma Group General Information
Description
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
Contact Information
Website
www.maynepharma.comCorporate Office
- 1538 Main North Road
- Salisbury, South Australia 5106
- Australia
Corporate Office
- 1538 Main North Road
- Salisbury, South Australia 5106
- Australia
Mayne Pharma Group Stock Performance
As of 10-Feb-2025, Mayne Pharma Group’s stock price is $3.64. Its current market cap is $296M with 81.2M shares.
(As of Monday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$3.64 | $2.94 | $2.44 - $4.92 | $296M | 81.2M | 149K | -$1.44 |
Mayne Pharma Group Financials Summary
As of 30-Jun-2024, Mayne Pharma Group has a trailing 12-month revenue of $254M.
In Thousands, USD |
TTM 30-Jun-2024 | FY 2024 30-Jun-2024 | FY 2023 30-Jun-2023 | FY 2022 30-Jun-2022 |
---|---|---|---|---|
EV | 185,923 | 185,923 | 128,693 | 516,311 |
Revenue | 254,208 | 254,208 | 122,617 | 307,196 |
EBITDA | (100,498) | (100,498) | (160,523) | (120,259) |
Net Income | (114,182) | (114,182) | 78,824 | (190,835) |
Total Assets | 764,100 | 764,100 | 825,663 | 885,976 |
Total Debt | 25,948 | 25,948 | 31,445 | 284,565 |
Mayne Pharma Group Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Mayne Pharma Group Comparisons
Industry
Financing
Details
Mayne Pharma Group Competitors (16)
One of Mayne Pharma Group’s 16 competitors is Cipla, a Corporation company based in Mumbai, India.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Cipla | Corporation | Mumbai, India | ||||
Par Pharmaceutical Companies | Formerly PE-Backed | Woodcliff Lake, NJ | ||||
Jubilant Pharmova | Corporation | Noida, India | ||||
Novartis | Corporation | Basel, Switzerland | ||||
GSK | Corporation | Middlesex, United Kingdom |
Mayne Pharma Group Patents
Mayne Pharma Group Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20180140614-A1 | Corticosteriod containing foam compositions | Inactive | 15-Dec-2015 | ||
US-20190365783-A1 | Halobetasol foam composition and method of manufacture thereof | Inactive | 15-Dec-2015 | ||
US-20180140615-A1 | Method of manufacturing corticosteriod containing foam compositions | Inactive | 15-Dec-2015 | ||
AU-2016372790-A1 | Corticosteroid containing foam compositions and method of manufacture thereof | Inactive | 15-Dec-2015 | ||
US-10857159-B2 | Halobetasol foam composition and method of use thereof | Active | 15-Dec-2015 | A61K9/122 |
Mayne Pharma Group Signals
Mayne Pharma Group Investments & Acquisitions (17)
Mayne Pharma Group’s most recent deal was a Corporate Asset Purchase with EPI Health (Global Rights to the Rosacea Treatment RHOFADE) for . The deal was made on 26-Feb-2024.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
EPI Health (Global Rights to the Rosacea Treatment RHOFADE) | 26-Feb-2024 | Corporate Asset Purchase | Buildings and Property | ||
TherapeuticsMD ( Women's Healthcare products) | 03-Jan-2023 | Corporate Asset Purchase | Buildings and Property | ||
Mayne Pharma Group (US & Australian Rights to Halobetasol Foam & Related Assets) | 26-Oct-2018 | Corporate Asset Purchase | Buildings and Property | ||
INHIBITOR Therapeutics | 11-Jan-2018 | PIPE | Pharmaceuticals | ||
Glaxosmithkline (Dermatology foam assets and plaque psoriasis treatment Sorilux (calcipotriene)) | 18-Aug-2016 | Corporate Asset Purchase | Buildings and Property |
Mayne Pharma Group ESG
Risk Overview
Risk Rating
Updated August, 10, 2024
27.34 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile

Pharmaceuticals
Industry
of 853
Rank
Percentile

Pharmaceuticals
Subindustry
of 425
Rank
Percentile

Mayne Pharma Group Exits (4)
Mayne Pharma Group’s most recent exit was on 02-Aug-2016 from Teva Pharmaceuticals (US Generic Products Portfolio). The exit was categorized as .
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
Teva Pharmaceuticals (US Generic Products Portfolio) | 02-Aug-2016 | Completed |
|
||
Metrics Contract Services | 15-Nov-2012 | Completed |
|
||
PH&T | 24-Jun-2005 | Completed |
|
||
Wasserburger Arzneimittelwerk | 01-May-2004 | Merger/Acquisition | Completed |
Mayne Pharma Group FAQs
-
When was Mayne Pharma Group founded?
Mayne Pharma Group was founded in 1845.
-
Where is Mayne Pharma Group headquartered?
Mayne Pharma Group is headquartered in Salisbury, Australia.
-
What is the size of Mayne Pharma Group?
Mayne Pharma Group has 160 total employees.
-
What industry is Mayne Pharma Group in?
Mayne Pharma Group’s primary industry is Drug Discovery.
-
Is Mayne Pharma Group a private or public company?
Mayne Pharma Group is a Public company.
-
What is Mayne Pharma Group’s stock symbol?
The ticker symbol for Mayne Pharma Group is MYX.
-
What is the current stock price of Mayne Pharma Group?
As of 10-Feb-2025 the stock price of Mayne Pharma Group is $3.64.
-
What is the current market cap of Mayne Pharma Group?
The current market capitalization of Mayne Pharma Group is $296M.
-
What is Mayne Pharma Group’s current revenue?
The trailing twelve month revenue for Mayne Pharma Group is $254M.
-
Who are Mayne Pharma Group’s competitors?
Cipla, Par Pharmaceutical Companies, Jubilant Pharmova, Novartis, and GSK are some of the 16 competitors of Mayne Pharma Group.
-
What is Mayne Pharma Group’s annual earnings per share (EPS)?
Mayne Pharma Group’s EPS for 12 months was -$1.44.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »